- Atlas
- Medicine & Health
- Precision Oncology
Precision Oncology
Precision oncology is the practice of choosing a cancer treatment by reading the molecular features of a patient's tumor rather than by its location in the body or its appearance under a microscope alone.
10 frameworks, from 1970 to today · Oncology · Medicine & Health
- Somatic Mutation Theory of Cancer 1970-Present
- Targeted Therapy and Companion Diagnostics 1998-Present
- Oncogene Addiction 2000-Present
- Molecular Taxonomy of Cancer 2005-Present
- Somatic evolution in cancer 2005-Present
- Molecular Tumor Board 2010-Present
- Liquid biopsy 2012-Present
- Comprehensive Genomic Profiling 2013-Present
- Genotype-Directed Immunotherapy 2015-Present
- Tumor-Agnostic Drug Development 2017-Present
Overview
Precision oncology is the practice of choosing a cancer treatment by reading the molecular features of a patient's tumor rather than by its location in the body or its appearance under a microscope alone. Its central claim is that two breast cancers that look identical down the microscope may be driven by different broken genes, respond to different drugs, and behave as different diseases1. What is at stake is the oldest problem in cancer medicine: most conventional chemotherapy is a blunt instrument that kills dividing cells wherever they are, and works well only in some tumors. Precision oncology tries to match the drug to the defect, so that treatment is both more effective and less toxic2. The field grew out of a convergence of cancer genetics, medicinal chemistry, pathology, and clinical trial design over roughly the last fifty years, and it has changed not only what drugs are given but how cancers are named, how trials are run, and what a diagnosis even is.
The genetic view of cancer takes shape
The intellectual foundation was laid in the decades after the Second World War, when researchers established that cancer is fundamentally a disease of mutated genes. The discovery of the Philadelphia chromosome in chronic myeloid leukemia in 1960, and later the identification of the BCR-ABL fusion it produces, showed that a single chromosomal accident could drive a cancer. In the 1970s and 1980s, the discovery of oncogenes—normal genes that, when mutated or overexpressed, push cells toward uncontrolled growth—and of tumor suppressor genes such as TP53, which normally restrain growth, gave the field a vocabulary. By the 1980s, the somatic mutation theory was well established: cancers arise from mutations acquired in the body's cells over a lifetime, not inherited in the germline (though inherited mutations can raise risk).
This mattered clinically because it suggested a target. If a cancer depends on one hyperactive gene product, a drug that blocks that product might stop the cancer while sparing normal tissue. The term for this dependency is oncogene addiction: a tumor cell that has built its growth machinery around one mutant protein often cannot survive without it, even though normal cells can. The concept was articulated and popularized in the early 2000s, but its proof came earlier.
Imatinib and the first targeted success
The decisive demonstration was imatinib (Gleevec), developed in the late 1990s by a team at Novartis and approved by the U.S. Food and Drug Administration in 2001 for chronic myeloid leukemia. Imatinib is a small molecule that inhibits the ABL kinase, the enzyme produced by the BCR-ABL fusion31. In patients whose leukemia carried the fusion, the drug produced dramatic and durable remissions—a result that had been almost unimaginable in a cancer previously managed with interferon and stem-cell transplant. The lesson was not just that a targeted drug could work, but that it worked because the tumor carried the target. Testing for the fusion became part of diagnosis.
The same logic soon reached solid tumors. In the early 2000s, the drug trastuzumab, an antibody against the HER2 receptor, was shown to benefit breast cancers that overexpress HER2—roughly a fifth of cases. The companion test that identified those tumors, an immunohistochemical or fluorescence in situ hybridization assay for HER2, became one of the first widely used companion diagnostics: a test required to determine whether a drug is appropriate. Later, lung cancers with activating mutations in the EGFR kinase were found to respond to gefitinib and erlotinib, and the anaplastic lymphoma kinase (ALK) fusion in a subset of lung cancers to crizotinib. Each case followed the same pattern: identify a molecular subset, develop a drug against it, and require a test to find the patients.
Molecular taxonomy and the pathologist's new tools
As targeted drugs multiplied, the old classification of cancer by organ of origin and microscopic appearance began to strain1. Two lung adenocarcinomas that looked the same might harbor EGFR, ALK, KRAS, or none of these, with very different treatment implications. The response was a molecular taxonomy: a classification layered onto histology that sorts tumors by their driver alterations4. This was not a rejection of the microscope but an addition to it5. Pathology departments added sequencing and immunohistochemistry panels, and the diagnosis of, say, lung cancer came to include a molecular report.
The technology that made this practical was next-generation sequencing, which by the 2010s could read many genes at once from a small tumor sample. Comprehensive genomic profiling—sequencing hundreds of cancer-relevant genes in a single assay—became commercially available and entered routine use for advanced cancers. It generated more information than any single oncologist could interpret, which gave rise to the molecular tumor board: a multidisciplinary meeting of oncologists, pathologists, geneticists, and bioinformaticians who review a patient's genomic report and recommend a treatment, often an off-label drug or a clinical trial. The tumor board is a distinctly modern institution, a place where the interpretation of genomic data is negotiated collectively6.
Resistance and the clonal view
Targeted therapy brought a new problem: resistance. Imatinib produced remissions, but many patients relapsed as leukemia cells acquired new mutations in the BCR-ABL kinase that prevented the drug from binding. The same pattern appeared in lung cancer, where EGFR-mutant tumors treated with gefitinib or erlotinib often developed a secondary T790M mutation. The explanation came from clonal evolution: a tumor is not a uniform mass but a population of genetically diverse cells, and a drug kills the sensitive majority while leaving resistant subclones to expand. This model, developed through the 2000s and 2010s, reframed cancer as an evolving ecosystem and made resistance a predictable feature of targeted treatment rather than an occasional failure. It drove the development of second- and third-generation inhibitors (osimertinib for T790M-mutant lung cancer, for example) and of combination strategies meant to suppress resistance before it emerges.
Liquid biopsy and the monitoring problem
Repeated tumor biopsies are invasive and often impossible when a tumor is inaccessible or has shrunk. The solution was to detect tumor DNA in the blood7. Circulating tumor DNA (ctDNA)—fragments of DNA released by dying tumor cells into the bloodstream—can be sequenced from a blood draw, a procedure called liquid biopsy. The approach matured through the 2010s: it can reveal a tumor's mutations when tissue is unavailable, track whether a treatment is working by measuring ctDNA levels, and detect the emergence of resistance mutations before a scan shows progression. It remains an area of active development, with questions about sensitivity in early-stage disease and about how to act on the results.
Immunotherapy meets genomics
A parallel strand came from cancer immunology8. Immune checkpoint inhibitors—drugs that release the brakes on the immune system—were shown in the 2010s to produce durable responses in some cancers. The puzzle was which patients would respond8. One answer was genomic: tumors with many mutations, measured as tumor mutational burden, tend to produce more abnormal proteins that the immune system can recognize, and some such tumors respond better9. Another was the presence of mismatch-repair deficiency, a genetic state that generates thousands of mutations and, in 2017, led to the first approval of a drug (pembrolizumab) for any solid tumor with that biomarker regardless of where it arose. This was a landmark for genotype-directed immunotherapy: treatment chosen by a genomic feature rather than by cancer type.
Tumor-agnostic drug development
That 2017 approval crystallized a broader shift: tumor-agnostic, histology-independent drug development. Traditionally, a drug was approved for a cancer type—breast, lung, colon. But if a mutation drives cancer regardless of tissue of origin, a drug against it might work across types. The mismatch-repair approval was followed by others, including approvals for NTRK fusion-positive tumors and for BRAF V600E-mutant tumors across multiple histologies. The approach is not universal—the same mutation can behave differently in different tissues—but it established that a molecular feature can be a valid indication in its own right, and it forced regulators and trial designers to rethink what a "disease" is.
Where the field stands
Precision oncology today is built on these layers: molecular taxonomy and comprehensive genomic profiling as the diagnostic backbone; companion diagnostics to gate access to targeted drugs; molecular tumor boards to interpret the data; ctDNA monitoring to track response and resistance; and genotype-directed immunotherapy and tumor-agnostic approvals as the newest frontier. The field has real successes—imatinib in CML, EGFR and ALK inhibitors in lung cancer, HER2-directed therapy in breast cancer—and real limits. Most advanced cancers still lack a targetable driver, many targeted responses are temporary, and the cost and complexity of genomic testing raise questions of access. The open questions are biological and practical at once: how to predict which alterations are truly drivers, how to combine drugs to outpace clonal evolution, how to make liquid biopsy reliable enough for early detection, and how to extend the logic of precision to the immune system and to the tumor's surrounding tissue. The field's history is the story of a single idea—that the molecular details of a cancer should determine its treatment—being pursued through successive technologies, each solving the problem the last one exposed.
References
- Personalized medicine (Cancer genomics), Wikipedia
- Targeted therapy, Wikipedia
- Imatinib, Wikipedia
- Ash Alizadeh, Wikipedia
- Molecular pathology, Wikipedia
- Molecular tumor board, Wikipedia
- Circulating tumor DNA, Wikipedia
- Cancer immunotherapy (introduction, Immune checkpoint blockade), Wikipedia
- Tumor mutational burden, Wikipedia
The frameworks of Precision Oncology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1970-Present
Somatic Mutation Theory of Cancer
What causes a normal cell to become cancerous?
- 1998-Present
Targeted Therapy and Companion Diagnostics
How can a drug be matched to a tumor's molecular defect?
- 2000-Present
- 2005-Present
- 2005-Present
Somatic evolution in cancer
How do tumors change and become resistant to treatment?
- 2010-Present
Molecular Tumor Board
How should genomic data be turned into a treatment decision?
- 2012-Present
- 2013-Present
Comprehensive Genomic Profiling
How can many cancer genes be read at once?
- 2015-Present
Genotype-Directed Immunotherapy
Which patients will respond to immune-stimulating drugs?
- 2017-Present
Tumor-Agnostic Drug Development
Can a drug be approved for a mutation rather than a cancer type?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Targeted Therapy and Companion Diagnostics grew out of Somatic Mutation Theory of Cancer
The somatic mutation theory supplied the premise that a cancer's acquired mutations could be targeted by drugs. Imatinib's development against the BCR-ABL fusion and the requirement to test for the fusion before treatment turned that premise into targeted therapy with companion diagnostics.
Carried by Brian Druker; Imatinib (Gleevec).
Molecular Taxonomy of Cancer grew out of Targeted Therapy and Companion Diagnostics
As targeted drugs required identifying the molecular subsets that would respond, classification of tumors by driver alteration was layered onto histology. Companion diagnostics for HER2, EGFR and ALK were the practical instruments that made molecular taxonomy clinically necessary.
Molecular Tumor Board grew out of Molecular Taxonomy of Cancer
Molecular taxonomy produced genomic reports too complex for a single oncologist to interpret, and the molecular tumor board was created as the multidisciplinary forum for acting on them. The board's task is to translate a tumor's molecular classification into a treatment recommendation.
Tumor-Agnostic Drug Development grew out of Genotype-Directed Immunotherapy
The 2017 approval of pembrolizumab for any mismatch-repair-deficient solid tumor was the first genotype-directed immunotherapy to be approved across histologies. That approval became the model for tumor-agnostic drug development, which generalized the principle that a molecular feature can be an indication in its own right.
Carried by Pembrolizumab (Keytruda).
Oncogene Addiction influenced by Targeted Therapy and Companion Diagnostics
The dramatic responses of BCR-ABL-positive leukemia to imatinib and of EGFR-mutant lung cancer to gefitinib provided the clinical evidence from which oncogene addiction was articulated as a general principle. The concept was formulated to explain why tumors with a single dominant driver regress when that driver is inhibited.
Carried by Charles Sawyers; Bernard Weinstein.
Somatic evolution in cancer influenced by Targeted Therapy and Companion Diagnostics
Resistance to imatinib and to EGFR inhibitors, in which new kinase mutations appeared in relapsed tumors, supplied the clinical puzzle that clonal evolution explained. The observation that drug-sensitive cells were killed while resistant subclones expanded drove the reframing of tumors as evolving populations.
Tumor-Agnostic Drug Development influenced by Targeted Therapy and Companion Diagnostics
Tumor-agnostic development extended the targeted-therapy logic that a drug should be matched to the molecular defect rather than to the organ of origin. The companion-diagnostic model of gating a drug by a molecular test was carried over into histology-independent approvals such as those for NTRK fusions.
Liquid biopsy influenced by Somatic evolution in cancer
The clonal-evolution view made resistance a predictable feature of targeted treatment, creating a need to monitor subclones over time without repeated biopsies. Liquid biopsy answered that need by sequencing circulating tumor DNA to track emerging resistance mutations.
Genotype-Directed Immunotherapy influenced by Comprehensive Genomic Profiling
Comprehensive genomic profiling made it possible to measure tumor mutational burden and detect mismatch-repair deficiency across many genes in one assay. Those genomic measurements became the biomarkers used to select patients for genotype-directed immunotherapy.
Genotype-Directed Immunotherapy influenced by Somatic evolution in cancer
The clonal model's emphasis on tumor heterogeneity and mutational accumulation provided part of the rationale for linking mutation burden to immune recognition. Tumors with many mutations, as described by somatic evolution, were proposed to present more abnormal proteins to the immune system.
Beyond the field
Where Precision Oncology's ideas came from in other fields, and what they led to there: the strongest 12 of 44 links.
Somatic Mutation Theory of Cancer influenced Cancer Genetics in Medical Genetics
The somatic mutation theory of cancer, holding that cancer arises from accumulated mutations in somatic cells, is the conceptual foundation on which cancer genetics built its search for inherited and acquired cancer genes. Cancer genetics extended the somatic mutation account to germline susceptibility.
Somatic Mutation Theory of Cancer replaced Local-Disease Model in Oncology
The local-disease model held that cancer is confined to the primary site and its regional spread, justifying radical local surgery. The somatic mutation theory replaced it as the working view by locating the disease in genetic changes within cells, with metastasis following from those changes.
Targeted Therapy and Companion Diagnostics influenced Personalized medicine in Clinical Decision Science
Targeted therapy with companion diagnostics gave personalized medicine its working model: a molecular test selects patients for a matched drug, as with trastuzumab and HER2 testing. This test-then-treat pairing, established from the late 1990s, is the template the broader personalized medicine programme generalised beyond oncology.
Carried by Trastuzumab; Imatinib.
Oncogene Addiction grew out of Somatic Mutation Theory in Oncology
Oncogene addiction is a refinement of the somatic mutation theory: it holds that some tumours remain dependent on a single mutated oncogene even after many other mutations have accumulated. The idea grew directly out of mutation-based accounts of cancer and gave them a therapeutic corollary.
Molecular Taxonomy of Cancer grew out of Molecular Oncology in Molecular Biology
The molecular taxonomy of cancer grew directly out of molecular oncology: expression profiling and mutation analysis were used to regroup tumours by molecular signature rather than by site and histology. It is the classificatory branch of that molecular programme.
Somatic evolution in cancer grew out of Somatic Mutation Theory in Oncology
Somatic evolution in cancer generalises the somatic mutation theory by treating tumour cell populations as subject to mutation, selection and drift. It grew directly out of the mutation theory by adding population-genetic dynamics to it.
Molecular Tumor Board grew out of Multidisciplinary Tumor Board and Combined-Modality Sequencing in Surgical Oncology
The molecular tumour board is a direct descendant of the multidisciplinary tumour board: it keeps the collective decision-making format but adds molecular profiling data to the case review. The institutional structure was carried over and extended.
Comprehensive Genomic Profiling grew out of Biomarker and Companion Diagnostic Model in Pharmacogenomics
The biomarker and companion diagnostic model is the framework that comprehensive genomic profiling formalized and scaled up: companion diagnostics established that a genomic biomarker must be validated and tied to a specific drug, and profiling extended this from single biomarkers to hundreds of genes at once.
Comprehensive Genomic Profiling influenced by Molecular Oncology in Molecular Biology
Comprehensive genomic profiling is a direct application of molecular oncology: the systematic sequencing of tumor genes grew out of the molecular oncology programme that identified cancer-driving mutations and their clinical significance.
Tumor-Agnostic Drug Development influenced by Targeted therapy in Medical Oncology
Tumor-agnostic drug development arose from targeted therapy's logic that a drug should follow its molecular target rather than the tissue of origin; the first tumor-agnostic approvals extended targeted agents to any tumor carrying the target mutation.
Somatic Mutation Theory of Cancer led to Tumor Suppressor Genetics in Pediatric Hematology And Oncology
The tumor suppressor concept developed within the somatic mutation theory of cancer, adding recessive loss-of-function mutations to the dominant oncogene model. The two-hit hypothesis was presented as a special case of the somatic mutation account.
Carried by Alfred Knudson.
Targeted Therapy and Companion Diagnostics influenced Biomarker-Based Staging and Preclinical Disease in Neurodegenerative Diseases
Targeted therapy and companion diagnostics in precision oncology established the model of using a molecular marker to define a disease subset and guide intervention. Biomarker-based preclinical staging of neurodegenerative disease adopted this marker-defined stratification logic.

Precision Oncology is a planet in Nousfarer
Its city has a tower for each of these 10 frameworks. Land, walk in, and climb one concept at a time.
Land on Precision OncologyRelated fields
Fields its ideas are linked to
- Pharmacogenomics 6 links
- Tumor Immunology 5 links
- Medical Oncology 5 links
- Oncology 5 links
- Medicinal Chemistry 4 links
- Molecular Biology 3 links
- Clinical Decision Science 2 links
- Clinical Immunology 2 links
- Pediatric Hematology And Oncology 2 links
- Medical Genetics 1 link
- Single Cell Genomics 1 link
- Clinical Medicine 1 link
More in Oncology
- Cancer Prevention And Screening
- Hematologic Malignancies
- Medical Oncology
- Oncology
- Radiation Oncology
- Surgical Oncology
See where Precision Oncology sits on the Map of Human Knowledge